Jordi Segura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3575189/publications.pdf Version: 2024-02-01



LODDI SECURA

#	Article	IF	CITATIONS
1	Usefulness of Saliva for Measurement of 3,4-Methylenedioxymethamphetamine and Its Metabolites: Correlation with Plasma Drug Concentrations and Effect of Salivary pH. Clinical Chemistry, 2001, 47, 1788-1795.	1.5	120
2	Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo). Analytical Biochemistry, 2008, 383, 243-254.	1.1	78
3	Progress in the Removal of Di-[2-Ethylhexyl]-Phthalate as Plasticizer in Blood Bags. Transfusion Medicine Reviews, 2012, 26, 27-37.	0.9	78
4	Targeting tryptophan and tyrosine metabolism by liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2016, 1434, 91-101.	1.8	72
5	High-Throughput and Sensitive Screening by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry of Diuretics and other Doping Agents. European Journal of Mass Spectrometry, 2008, 14, 191-200.	0.5	63
6	Investigation of endogenous corticosteroids profiles in human urine based on liquid chromatography tandem mass spectrometry. Analytica Chimica Acta, 2014, 812, 92-104.	2.6	60
7	Evaluation of protein <i>N</i> â€glycosylation in 2â€DE: Erythropoietin as a study case. Proteomics, 2007, 7, 4278-4291.	1.3	49
8	Plasma and urinary markers of oral testosterone undecanoate misuse. Steroids, 2002, 67, 39-50.	0.8	47
9	Evaluation of different scan methods for the urinary detection of corticosteroid metabolites by liquid chromatography tandem mass spectrometry. Journal of Mass Spectrometry, 2009, 44, 929-944.	0.7	46
10	Procedures for monitoring recombinant erythropoietin and analogues in doping control. Analytical and Bioanalytical Chemistry, 2007, 388, 1521-1529.	1.9	44
11	Immunological screening of drugs of abuse and gas chromatographic–mass spectrometric confirmation of opiates and cocaine in hair. Biomedical Applications, 1999, 724, 9-21.	1.7	43
12	Quantifying endogenous androgens, estrogens, pregnenolone and progesterone metabolites in human urine by gas chromatography tandem mass spectrometry. Talanta, 2017, 169, 20-29.	2.9	40
13	Urinary diâ€{2â€ethylhexyl)phthalate metabolites in athletes as screening measure for illicit blood doping: a comparison study with patients receiving blood transfusion. Transfusion, 2010, 50, 145-149.	0.8	39
14	Oral Testosterone Administration Detected by Testosterone Glucuronidation Measured in Blood Spots Dried on Filter Paper. Clinical Chemistry, 2000, 46, 515-522.	1.5	37
15	Screening for anabolic steroids in sports: Analytical strategy based on the detection of phase I and phase II intact urinary metabolites by liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2015, 1389, 65-75.	1.8	37
16	Determination of five di-(2-ethylhexyl)phthalate metabolites in urine by UPLC–MS/MS, markers of blood transfusion misuse in sports. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 908, 113-121.	1.2	36
17	Detection of testosterone esters in human plasma. Journal of Mass Spectrometry, 1995, 30, 1393-1404.	0.7	35
18	Plasticizers excreted in urine: indication of autologous blood transfusion in sports. Transfusion, 2012, 52, 647-657.	0.8	35

Jordi Segura

#	Article	IF	CITATIONS
19	Quantitation of 17β-nandrolone metabolites in boar and horse urine by gas chromatography–mass spectrometry. Analytica Chimica Acta, 2007, 586, 184-195.	2.6	32
20	Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport. Clinical Chemistry and Laboratory Medicine, 2005, 43, 75-85.	1.4	30
21	Assessing the instability of the isoelectric focusing patterns of erythropoietin in urine. Electrophoresis, 2006, 27, 4387-4395.	1.3	30
22	Urinary metabolic profile of 19â€norsteroids in humans: glucuronide and sulphate conjugates after oral administration of 19â€norâ€4â€androstenediol. Rapid Communications in Mass Spectrometry, 2008, 22, 3035-3042.	0.7	29
23	Recombinant erythropoietin found in seized blood bags from sportsmen. Haematologica, 2008, 93, 313-314.	1.7	28
24	Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 1169-1177.	1.4	26
25	Evaluation of two glucuronides resistant to enzymatic hydrolysis as markers of testosterone oral administration. Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 212-218.	1.2	25
26	Detection of erythropoiesisâ€ s timulating agents in a single dried blood spot. Drug Testing and Analysis, 2018, 10, 1496-1507.	1.6	25
27	Growth Hormone in Sport: Beyond Beijing 2008. Therapeutic Drug Monitoring, 2009, 31, 3-13.	1.0	23
28	Determination of Recent Growth Hormone Abuse Using a Single Dried Blood Spot. Clinical Chemistry, 2016, 62, 1353-1360.	1.5	22
29	Detection of Stimulated Erythropoiesis by the RNA-Based 5'-Aminolevulinate Synthase 2 Biomarker in Dried Blood Spot Samples. Clinical Chemistry, 2019, 65, 1563-1571.	1.5	21
30	Growth hormone secretagogues: out of competition. Analytical and Bioanalytical Chemistry, 2012, 402, 1101-1108.	1.9	18
31	Evaluation of the reporting level to detect triamcinolone acetonide misuse in sports. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 94-102.	1.2	18
32	Whole Blood Storage in CPDA1 Blood Bags Alters Erythrocyte Membrane Proteome. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-12.	1.9	18
33	Alterations of the erythrocyte membrane proteome and cytoskeleton network during storage – a possible tool to identify autologous blood transfusion. Drug Testing and Analysis, 2012, 4, 882-890.	1.6	17
34	Ultra high performance liquid chromatography tandem mass spectrometric detection of glucuronides resistant to enzymatic hydrolysis: Implications to doping control analysis. Analytica Chimica Acta, 2015, 895, 35-44.	2.6	17
35	Detection of the administration of 17 <i>β</i> â€nortestosterone in boars by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 1863-1870.	0.7	16
36	ls antiâ€doping analysis so far from clinical, legal or forensic targets?: The added value of close relationships between related disciplines. Drug Testing and Analysis, 2009, 1, 479-484.	1.6	16

Jordi Segura

#	Article	IF	CITATIONS
37	Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 844-852.	1.4	15
38	Automation of RNA-based biomarker extraction from dried blood spots for the detection of blood doping. Bioanalysis, 2020, 12, 729-736.	0.6	15
39	Evaluation of immunoassays for the measurement of insulin and C-peptide as indirect biomarkers of insulin misuse in sport: Values in selected population of athletes. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 793-799.	1.4	14
40	Analysis of urinary human growth hormone (hGH) using hydrogel nanoparticles and isoform differential immunoassays after short recombinant hGH treatment: Preliminary results. Journal of Pharmaceutical and Biomedical Analysis, 2013, 85, 194-197.	1.4	14
41	Characterisation of the 5 kDa growth hormone isoform. Growth Factors, 2008, 26, 152-162.	0.5	13
42	Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: Immunoassay-based measurement in urine samples. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 1003-1010.	1.4	12
43	Intermittent hypoxia exposure in a hypobaric chamber and erythropoietin abuse interpretation. Journal of Sports Sciences, 2007, 25, 1241-1250.	1.0	11
44	Bioanalytical techniques in discrimination between therapeutic and abusive use of drugs in sport. Bioanalysis, 2016, 8, 965-980.	0.6	11
45	Gas chromatography–mass spectrometry method for the analysis of 19-nor-4-androstenediol and metabolites in human plasma: Application to pharmacokinetic studies after oral administration of a prohormone supplement. Steroids, 2008, 73, 751-759.	0.8	10
46	Urinary cysteinyl progestogens: Occurrence and origin. Journal of Steroid Biochemistry and Molecular Biology, 2015, 152, 53-61.	1.2	10
47	Generation of 5 and 17 kDa human growth hormone fragments through limited proteolysis. Growth Factors, 2009, 27, 255-264.	0.5	9
48	Current strategic approaches for the detection of blood doping practices. Forensic Science International, 2011, 213, 42-48.	1.3	9
49	Detection and differentiation of 22kDa and 20kDa Growth Hormone proteoforms in human plasma by LC-MS/MS. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 284-290.	1.1	9
50	Clarification on the detection of epoetin delta and epoetin omega using isoelectric focusing. American Journal of Hematology, 2008, 83, 754-754.	2.0	8
51	Formation of Δ1 and Δ6 testosterone metabolites by human hepatocytes. Steroids, 2015, 95, 66-72.	0.8	7
52	Recent progress in the detection of the administration of natural hormones: Special focus on Testosterone. Toxin Reviews, 1999, 18, 125-144.	1.5	6
53	On the road of dried blood spot sampling for antidoping tests: Detection of GHRPâ€2 abuse. Drug Testing and Analysis, 2021, 13, 510-522.	1.6	5
54	If you play with fire, you may get burned. Drug Testing and Analysis, 2020, 12, 582-587.	1.6	3

#	Article	IF	CITATIONS
55	Distinction Between Endogenous and Exogenous Erythropoietin: Marker Methods. Growth Hormone, 2011, , 151-161.	0.2	3
56	Research Spotlight: Bioanalysis and Analytical Services Research Group at The Municipal Institute for Medical Research IMIM-Hospital del Mar, Spain. Bioanalysis, 2009, 1, 1403-1409.	0.6	0